北海康成-B盘中涨超35%,年内累计涨幅已逾13倍。截至发稿,股价上涨31.85%,现报1.78港元,成交额4255.90万港元。5月15日,国家药品监督管理局通过优先审评审批程序批准北海康成申报的注射用维拉苷酶β(商品名:戈芮宁)上市,适用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的长期酶替代治疗。7月3日,戈谢病一类创新药戈芮宁开出首张处方,首位患者已在新华医院接受治疗。北海康成创始人、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.